SOLOAGO: Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
Study Details
Study Description
Brief Summary
The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
It is currently established that obtaining a large number of oocytes is a key of success in IVF/ICSI cycles. However, it is also a risk factor for ovarian hyperstimulation syndrome (OHSS) and a risk factor of implantation failure after fresh embryo transfer because of the alteration of endometrial receptivity. A freeze all strategy can be proposed to avoid these risks but vitrification of embryos, although more efficient than slow freezing in terms of embryo survival, is not without risk. Furthermore, proper endometrial and embryo timing for frozen-thawed embryo transfer is still debated.
Recent preliminary works suggest another possible way to combine an optimal ovarian response with the recovery of a large number of oocytes, good chances of implantation and a reduced risk of OHSS. To achieve this goal, ovulation triggering and luteal phase support need to be modified together. The human chorionic gonadotropin (hCG) (mimicking the Luteinising Hormone (LH)peak to trigger ovulation) that induces OHSS is replaced by an a GnRH agonist (GnRHa) triggering allowing an endogenous peak of Follicle Stimulating Hormone (FSH) and LH. Then, the usual support of the luteal phase by exogenous vaginal progesterone, whose absorption seems to be suboptimal for about 30% of patients, is replaced by endogenous progesterone production by the corpora lutea, supported by the maintenance of LH activity through the continuation of agonist of gonadotropin releasing hormone (AgoGnRH) in the luteal phase. Pilot studies show that a 10% to 15% increase in ongoing pregnancy rates can be expected with this type of protocol. The objective of our study is to demonstrate an increase in ongoing pregnancy rate per cycle with this new strategy combining GnRHa triggering and GnRHa luteal phase support compared to the reference protocol (hCG triggering and exogenous progesterone luteal phase support).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Ovulation triggering with hCG + Luteal phase support with vaginal progesterone hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg tid) vaginally from the evening of the oocyte retrieval until the first pregnancy test |
Drug: Ovulation induction with hCG + Luteal phase support with vaginal progesterone
hCG 250µg subcutaneously between 36h and 38h before oocyte retrieval + Progesterone 600mg/d (200mg morning, noon and evening) vaginally from the evening of the puncture until the pregnancy test result
|
| Experimental: Ovulation triggering with Triptorelin + Luteal phase support with Nafarelin Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test |
Drug: Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin
Triptorelin 0.2 mg subcutaneously between 36h and 38h before oocyte retrieval as a single dose Nafarelin 400µg /day (200µg in the morning 200µg in the evening) nasally from the evening of the oocyte retrieval until the first pregnancy test
|
Outcome Measures
Primary Outcome Measures
- Live birth, defined as the presence of a live birth after 22 weeks' gestation. Twin pregnancies will be counted as a single birth. [22 weeks' gestation]
To demonstrate an increase in the rate of live births after 22 weeks' amenorrhoea (SA) per cycle with induction and support by GnRH agonist compared with the reference protocol combining induction by hCG and luteal support by exogenous vaginal progesterone
Secondary Outcome Measures
- Embryo implantation defined as the presence of a gestational sac on the first ultrasound (5-8 WG) [5-8 weeks' gestation]
Demonstrate improvement of embryo implantation rates with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Pregnancy defined as an hCG level > 10 IU/ml 14 days after oocyte retrieval. [14 days after oocyte retrieval.]
Demonstrate an improvement in pregnancy rate with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Clinical pregnancy, defined as an intrauterine gestational sac with embryo showing cardiac activity on ultrasound at 5-10 WG [5-10 weeks' gestation]
Demonstrate an improvement in clinical pregnancy rate with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Miscarriage prior to 12 WG, defined as the termination of a pregnancy prior to 12 WG. [12 weeks' gestation]
Demonstrate a decrease in the rate of miscarriage per pregnancy with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Ongoing pregnancy, defined as the presence of an intra-uterine sac with an embryo with cardiac activity visible on ultrasound between 11 weeks of gestations(WG) and 13 WG+6 days (first trimester ultrasound). [first trimester ultrasound (11 weeks of gestation and 13weeks of gestation +6days)]
Demonstrate an increase ongoing pregnancy rate at 12 weeks of gestation (12 WG) per cycle with GnRHa triggering and GnRHa luteal phase support compared with the reference protocol: hCG triggering and exogenous vaginal progesterone luteal phase support.
- Number of patients with gravidic hypertension and its onset, [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Number of patients with pre-eclampsia and its onset, [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Number of patients with gestational diabetes and its onset [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Number of patients with term and mode of delivery [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Number of patients with medical termination of pregnancy [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Number of patients with late miscarriage (between 12 and 22 WG) [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Number of patients with fetal death in utero [between 12 weeks of gestation and 22 weeks of gestation]
Compare the impact on obstetric data with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Ovarian hyperstimulation syndrome, defined as the presence of moderate to severe syndrome, early and late. Early defined as the period before D10 post retrieval and late defined as pregnancy related OHSS, after D10 post oocyte retrieval [before Day 10 post retrieval and after Day 10 post oocyte retrieval]
Demonstrate a decrease in the rate of moderate to severe and early and late OHSS with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Progesterone levels on day of oocyte pick up and at Day 7 post oocyte pick up. [Day 7 post oocyte pick up]
Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Estradiol levels on day of oocyte pick up and at Day 7 post oocyte pick up. [Day 7 post oocyte pick up]
Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- LH levels on day of oocyte pick up and at Day 7 post oocyte pick up. [Day 7 post oocyte pick up]
Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- hCG levels on day of oocyte pick up and at Day 7 post oocyte pick up. [Day 7 post oocyte pick up]
Compare the evolution of the corpus luteum in the luteal phase with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Progesterone levels during follow-up, presence of pregnancy and presence of miscarriage. [19 months]
Assess the association of progesterone levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- Estradiol levels during follow-up, presence of pregnancy and presence of miscarriage. [19 months]
Assess the association of estradiol levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- LH levels during follow-up, presence of pregnancy and presence of miscarriage. [19 months]
Assess the association of LH levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- hCG levels during follow-up, presence of pregnancy and presence of miscarriage. [19 months]
Assess the association of hCG levels with pregnancy and miscarriage throughout follow-up with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
- All adverse events up to delivery [19 months]
Evaluate the side effects with GnRHa triggering and GnRHa luteal phase support compared to hCG induction and exogenous vaginal progesterone luteal support.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law.
-
Patients aged 18 to 39 included
-
First or second attempt of IVF or ICSI
-
BMI < 35 kg/m2
-
Anti-Mullerian hormone (AMH) > 1 ng/ml (= 7 pmol/L) and/or antral follicle count ≥ 8
-
AMH < 5 ng/ml and/or antral follicle count <40
-
Treatment with recombinant FSH
-
Antagonist protocol (with pre-treatment or not)
-
Initial dose of recombinant FSH between 75 and 450 IU
-
Signed informed consent
-
Affiliation to the social security system (excluding AME)
Exclusion Criteria:
-
Patient or partner with HIV, hepatitis B virus (HBV) or Hepatitis C Virus (HCV)
-
ICSI with sperm from testicular biopsy
-
Pre-implantation diagnosis
-
Hypogonadotropic hypogonadism (amenorrhea or spaniomenorrhea with basal LH <1.2 IU/L)
-
History of severe ovarian hyperstimulation syndrome (OHSS)
-
Unoperated hydrosalpinx
-
Intracavitary polyps or myomas deforming the cavity
-
Known hypersensitivity to the investigational drugs and/or their excipients (human chorionic gonadotropin, progesterone, nafarelin acetate, GnRH, GnRH analogues, mannitol, sodium chloride, water for injection, glacial acetic acid, Sodium hydroxide and/or hydrochloric acid, sorbitol, purified water, benzalkonium chloride, sunflower oil, soybean lecithin, gelatin, glycerol, titanium dioxide (E171), methionine, poloxamer 18, phosphoric acid).
-
Gynaecological bleeding or genital haemorrhage
-
Tumours of the hypothalamus or pituitary gland
-
Ovarian enlargement or cysts unrelated to polycystic ovary syndrome
-
Severe adenomyosis requiring a long protocol
-
Carcinoma of the ovary, uterus or breast
-
Active thromboembolic events
-
Severe impairment of liver function
-
Breastfeeding women
-
Patients under court protection, guardianship or curators
-
Current participation in another therapeutic interventional trial on the day of inclusion
-
Patients who do not speak or understand French
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Maeliss Peigné | Bondy | France |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APHP220667